|
1
|
von Neubeck C, Seidlitz A, Kitzler HH,
Beuthien-Baumann B and Krause M: Glioblastoma multiforme: Emerging
treatments and stratification markers beyond new drugs. Br J
Radiol. 88:201503542015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Buczkowicz P and Hawkins C: Pathology,
molecular genetics, and epigenetics of diffuse intrinsic pontine
glioma. Front Oncol. 5:1472015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pace A, Dirven L, Koekkoek JAF, Golla H,
Fleming J, Rudà R, Marosi C, Le Rhun E, Grant R, Oliver K, et al
European Association of Neuro-Oncology palliative care task force:
European Association for Neuro-Oncology (EANO) guidelines for
palliative care in adults with glioma. Lancet Oncol. 18:e330–e340.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alexander BM and Cloughesy TF: Adult
glioblastoma. J Clin Oncol. 35:2402–2409. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alvarez-Garcia I and Miska EA: MicroRNA
functions in animal development and human disease. Development.
132:4653–4662. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Griffiths-Jones S: The microRNA Registry.
Nucleic Acids Res. 32:D109–D111. 2004. View Article : Google Scholar :
|
|
8
|
Piva R, Spandidos DA and Gambari R: From
microRNA functions to microRNA therapeutics: Novel targets and
novel drugs in breast cancer research and treatment (Review). Int J
Oncol. 43:985–994. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Taylor MA and Schiemann WP: Therapeutic
opportunities for targeting microRNAs in cancer. Mol Cell Ther.
2:1–13. 2014. View Article : Google Scholar
|
|
10
|
Song MS and Rossi JJ: The anti-miR21
antagomir, a therapeutic tool for colorectal cancer, has a
potential synergistic effect by perturbing an
angiogenesis-associated miR30. Front Genet. 4:3012014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nana-Sinkam SP and Croce CM: Clinical
applications for microRNAs in cancer. Clin Pharmacol Ther.
93:98–104. 2013. View Article : Google Scholar
|
|
12
|
Hermansen SK and Kristensen BW: MicroRNA
biomarkers in glioblastoma. J Neurooncol. 114:13–23. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khalil S, Fabbri E, Santangelo A, Bezzerri
V, Cantù C, Di Gennaro G, Finotti A, Ghimenton C, Eccher A,
Dechecchi M, et al: miRNA array screening reveals cooperative
MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma.
Oncotarget. 7:28195–28206. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shu M, Zheng X, Wu S, Lu H, Leng T, Zhu W,
Zhou Y, Ou Y, Lin X, Lin Y, et al: Targeting oncogenic miR-335
inhibits growth and invasion of malignant astrocytoma cells. Mol
Cancer. 10:592011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chan XH, Nama S, Gopal F, Rizk P, Ramasamy
S, Sundaram G, Ow GS, Ivshina AV, Tanavde V, Haybaeck J, et al:
Targeting glioma stem cells by functional inhibition of a
prosurvival oncomiR-138 in malignant gliomas. Cell Rep. 2:591–602.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wagenaar TR, Zabludoff S, Ahn SM, Allerson
C, Arlt H, Baffa R, Cao H, Davis S, Garcia-Echeverria C, Gaur R, et
al: Anti-miR-21 suppresses hepatocellular carcinoma growth via
broad transcriptional network de-regulation. Mol Cancer Res.
13:1009–1021. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma L, Reinhardt F, Pan E, Soutschek J,
Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW and Weinberg RA:
Therapeutic silencing of miR-10b inhibits metastasis in a mouse
mammary tumor model. Nat Biotechnol. 28:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nielsen PE, Egholm M, Berg RH and Buchardt
O: Sequence-selective recognition of DNA by strand displacement
with a thymine-substituted polyamide. Science. 254:1497–1500. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nielsen PE: Targeting double stranded DNA
with peptide nucleic acid (PNA). Curr Med Chem. 8:545–550. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Borgatti M, Lampronti I, Romanelli A,
Pedone C, Saviano M, Bianchi N, Mischiati C and Gambari R:
Transcription factor decoy molecules based on a peptide nucleic
acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem.
278:7500–7509. 2003. View Article : Google Scholar
|
|
21
|
Gambari R: Peptide-nucleic acids (PNAs): A
tool for the development of gene expression modifiers. Curr Pharm
Des. 7:1839–1862. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gambari R: Biological activity and
delivery of peptide nucleic acids (PNA)-DNA chimeras for
transcription factor decoy (TFD) pharmacotherapy. Curr Med Chem.
11:1253–1263. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nielsen PE: Peptide nucleic acids (PNA) in
chemical biology and drug discovery. Chem Biodivers. 7:786–804.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nielsen PE: Gene targeting and expression
modulation by peptide nucleic acids (PNA). Curr Pharm Des.
16:3118–3123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Krupnik OV, Guscho Y, Sluchanko K, Nielsen
P and Lazurkin Y: Thermodynamics of the melting of PNA(2)/DNA
triple helices. J Biomol Struct Dyn. 19:535–542. 2001. View Article : Google Scholar
|
|
26
|
Bentin T and Nielsen PE: Superior duplex
DNA strand invasion by acridine conjugated peptide nucleic acids. J
Am Chem Soc. 125:6378–6379. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hatamoto M, Ohashi A and Imachi H: Peptide
nucleic acids (PNAs) antisense effect to bacterial growth and their
application potentiality in biotechnology. Appl Microbiol
Biotechnol. 86:397–402. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gambari R, Borgatti M, Bezzerri V, Nicolis
E, Lampronti I, Dechecchi MC, Mancini I, Tamanini A and Cabrini G:
Decoy oligodeoxyribonucleotides and peptide nucleic acids-DNA
chimeras targeting nuclear factor kappa-B: Inhibition of IL-8 gene
expression in cystic fibrosis cells infected with Pseudomonas
aeruginosa. Biochem Pharmacol. 80:1887–1894. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pandey VN, Upadhyay A and Chaubey B:
Prospects for antisense peptide nucleic acid (PNA) therapies for
HIV. Expert Opin Biol Ther. 9:975–989. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Manicardi A, Fabbri E, Tedeschi T, Sforza
S, Bianchi N, Brognara E, Gambari R, Marchelli R and Corradini R:
Cellular uptakes, biostabilities and anti-miR-210 activities of
chiral arginine-PNAs in leukaemic K562 cells. ChemBioChem.
13:1327–1337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fabbri E, Manicardi A, Tedeschi T, Sforza
S, Bianchi N, Brognara E, Finotti A, Breveglieri G, Borgatti M,
Corradini R, et al: Modulation of the biological activity of
microRNA-210 with peptide nucleic acids (PNAs). ChemMedChem.
6:2192–2202. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gambari R, Fabbri E, Borgatti M, Lampronti
I, Finotti A, Brognara E, Bianchi N, Manicardi A, Marchelli R and
Corradini R: Targeting microRNAs involved in human diseases: A
novel approach for modification of gene expression and drug
development. Biochem Pharmacol. 82:1416–1429. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fabani MM and Gait MJ: miR-122 targeting
with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids
(PNA), and PNA-peptide conjugates. RNA. 14:336–346. 2008.
View Article : Google Scholar :
|
|
34
|
Fabani MM, Abreu-Goodger C, Williams D,
Lyons PA, Torres AG, Smith KG, Enright AJ, Gait MJ and Vigorito E:
Efficient inhibition of miR-155 function in vivo by peptide nucleic
acids. Nucleic Acids Res. 38:4466–4475. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brown PN and Yin H: PNA-based microRNA
inhibitors elicit anti-inflammatory effects in microglia cells.
Chem Commun (Camb). 49:4415–4417. 2013. View Article : Google Scholar
|
|
36
|
Brognara E, Fabbri E, Aimi F, Manicardi A,
Bianchi N, Finotti A, Breveglieri G, Borgatti M, Corradini R,
Marchelli R, et al: Peptide nucleic acids targeting miR-221
modulate p27Kip1 expression in breast cancer MDA-MB-231
cells. Int J Oncol. 41:2119–2127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cheng CJ, Bahal R, Babar IA, Pincus Z,
Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM,
et al: MicroRNA silencing for cancer therapy targeted to the tumour
microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar
|
|
38
|
Brognara E, Fabbri E, Bazzoli E, Montagner
G, Ghimenton C, Eccher A, Cantù C, Manicardi A, Bianchi N, Finotti
A, et al: Uptake by human glioma cell lines and biological effects
of a peptide-nucleic acids targeting miR-221. J Neurooncol.
118:19–28. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cao X, Gu Y, Jiang L, Wang Y, Liu F, Xu Y,
Deng J, Nan Y, Zhang L, Ye J, et al: A new approach to screening
cancer stem cells from the U251 human glioma cell line based on
cell growth state. Oncol Rep. 29:1013–1018. 2013. View Article : Google Scholar
|
|
40
|
Abdullah Thani NA, Sallis B, Nuttall R,
Schubert FR, Ahsan M, Davies D, Purewal S, Cooper A and Rooprai HK:
Induction of apoptosis and reduction of MMP gene expression in the
U373 cell line by polyphenolics in Aronia melanocarpa and by
curcumin. Oncol Rep. 28:1435–1442. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pen A, Durocher Y, Slinn J, Rukhlova M,
Charlebois C, Stanimirovic DB and Moreno MJ: Insulin-like growth
factor binding protein 7 exhibits tumor suppressive and vessel
stabilization properties in U87MG and T98G glioblastoma cell lines.
Cancer Biol Ther. 12:634–646. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang JK, Yang JP, Tong J, Jing SY, Fan B,
Wang F, Sun GZ and Jiao BH: Exosomal miR-221 targets DNM3 to induce
tumor progression and temozolomide resistance in glioma. J
Neurooncol. 131:255–265. 2017. View Article : Google Scholar
|
|
43
|
Liu Q, Zou R, Zhou R, Gong C, Wang Z, Cai
T, Tan C and Fang J: miR-155 regulates glioma cells invasion and
chemosensitivity by p38 isforms in vitro. J Cell Biochem.
116:1213–1221. 2015. View Article : Google Scholar
|
|
44
|
Jung J, Yeom C, Choi YS, Kim S, Lee E,
Park MJ, Kang SW, Kim SB and Chang S: Simultaneous inhibition of
multiple oncogenic miRNAs by a multi-potent microRNA sponge.
Oncotarget. 6:20370–20387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Anjum K, Shagufta BI, Abbas SQ, Patel S,
Khan I, Shah SAA, Akhter N and Hassan SSU: Current status and
future therapeutic perspectives of glioblastoma multiforme (GBM)
therapy: A review. Biomed Pharmacother. 92:681–689. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lozada-Delgado EL, Grafals-Ruiz N and
Vivas-Mejía PE: RNA interference for glioblastoma therapy:
Innovation ladder from the bench to clinical trials. Life Sci.
188:26–36. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Touat M, Idbaih A, Sanson M and Ligon KL:
Glioblastoma targeted therapy: Updated approaches from recent
biological insights. Ann Oncol. 28:1457–1472. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li C, Sun J, Xiang Q, Liang Y, Zhao N,
Zhang Z, Liu Q and Cui Y: Prognostic role of microRNA-21 expression
in gliomas: A meta-analysis. J Neurooncol. 130:11–17. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Beyer S, Fleming J, Meng W, Singh R, Haque
SJ and Chakravarti A: The role of miRNAs in angiogenesis, invasion
and metabolism and their therapeutic implications in gliomas.
Cancers (Basel). 9. pp. E852017, View Article : Google Scholar
|
|
50
|
Wang Y, Wang X, Zhang J, Sun G, Luo H,
Kang C, Pu P, Jiang T, Liu N and You Y: MicroRNAs involved in the
EGFR/PTEN/AKT pathway in gliomas. J Neurooncol. 106:217–224. 2012.
View Article : Google Scholar
|
|
51
|
Regazzo G, Terrenato I, Spagnuolo M,
Carosi M, Cognetti G, Cicchillitti L, Sperati F, Villani V,
Carapella C, Piaggio G, et al: A restricted signature of serum
miRNAs distinguishes glioblastoma from lower grade gliomas. J Exp
Clin Cancer Res. 35:1242016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen L and Kang C: miRNA interventions
serve as 'magic bullets' in the reversal of glioblastoma hallmarks.
Oncotarget. 6:38628–38642. 2015.PubMed/NCBI
|
|
53
|
Areeb Z, Stylli SS, Koldej R, Ritchie DS,
Siegal T, Morokoff AP, Kaye AH and Luwor RB: MicroRNA as potential
biomarkers in Glioblastoma. J Neurooncol. 125:237–248. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ouyang Q, Xu L, Cui H, Xu M and Yi L:
MicroRNAs and cell cycle of malignant glioma. Int J Neurosci.
126:1–9. 2016. View Article : Google Scholar
|
|
55
|
Wang H, Xu T, Jiang Y, Yan Y, Qin R and
Chen J: MicroRNAs in human glioblastoma: From bench to beside.
Front Biosci. 20:105–118. 2015. View
Article : Google Scholar
|
|
56
|
Gambari R, Brognara E, Spandidos DA and
Fabbri E: Targeting oncomiRNAs and mimicking tumor suppressor
miRNAs: New trends in the development of miRNA therapeutic
strategies in oncology (Review). Int J Oncol. 49:5–32. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Finotti A, Allegretti M, Gasparello J,
Giacomini P, Spandidos DA, Spoto G and Gambari R: Liquid biopsy and
PCR-free ultrasensitive detection systems in oncology (Review). Int
J Oncol. 53:1395–1434. 2018.PubMed/NCBI
|
|
58
|
Li W, Guo F, Wang P, Hong S and Zhang C:
miR-221/222 confers radioresistance in glioblastoma cells through
activating Akt independent of PTEN status. Curr Mol Med.
14:185–195. 2014. View Article : Google Scholar
|
|
59
|
Chen L, Zhang J, Han L, Zhang A, Zhang C,
Zheng Y, Jiang T, Pu P, Jiang C and Kang C: Downregulation of
miR-221/222 sensitizes glioma cells to temozolomide by regulating
apoptosis independently of p53 status. Oncol Rep. 27:854–860.
2012.
|
|
60
|
Xie Q, Yan Y, Huang Z, Zhong X and Huang
L: MicroRNA-221 targeting PI3-K/Akt signaling axis induces cell
proliferation and BCNU resistance in human glioblastoma.
Neuropathology. 34:455–464. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Costa PM, Cardoso AL, Mano M and de Lima
MC: MicroRNAs in glioblastoma: Role in pathogenesis and
opportunities for targeted therapies. CNS Neurol Disord Drug
Targets. 14:222–238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yan Z, Che S, Wang J, Jiao Y, Wang C and
Meng Q: miR-155 contributes to the progression of glioma by
enhancing Wnt/β-catenin pathway. Tumour Biol. 36:5323–5331. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yang L, Li C, Liang F, Fan Y and Zhang S:
miRNA-155 promotes proliferation by targeting caudal-type homeobox
1 (CDX1) in glioma cells. Biomed Pharmacother. 95:1759–1764. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
De Santis R, Liepelt A, Mossanen JC, Dueck
A, Simons N, Mohs A, Trautwein C, Meister G, Marx G,
Ostareck-Lederer A, et al: miR-155 targets caspase-3 mRNA in
activated macrophages. RNA Biol. 13:43–58. 2016. View Article : Google Scholar :
|
|
66
|
Ergun S, Arman K, Temiz E, Bozgeyik I,
Yumrutaş Ö, Safdar M, Dağlı H, Arslan A and Oztuzcu S: Expression
patterns of miR-221 and its target caspase-3 in different cancer
cell lines. Mol Biol Rep. 41:5877–5881. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Bertucci A, Lülf H, Septiadi D, Manicardi
A, Corradini R and De Cola L: Intracellular delivery of peptide
nucleic acid and organic molecules using zeolite-L nanocrystals.
Adv Healthc Mater. 3:1812–1817. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bertucci A, Prasetyanto EA, Septiadi D,
Manicardi A, Brognara E, Gambari R, Corradini R and De Cola L:
Combined delivery of temozolomide and anti-miR221 PNA using
mesoporous silica nanoparticles induces apoptosis in resistant
glioma Cells. Small. 11:5687–5695. 2015. View Article : Google Scholar : PubMed/NCBI
|
